-
: Pathology Biomedical Data Sciences Postdoc Appointment Term: 1-year, renewable Appointment Start Date: 02/01/2026 How to Submit Application Materials: Please email vcharu@stanford.edu (link sends e-mail
-
: Pathology Biomedical Informatics Biomedical Data Sciences Postdoc Appointment Term: 1 year (renewable) Appointment Start Date: As soon as feasible; February 2026 How to Submit Application Materials: Please
-
conservation, polycentric governance, and environmental philanthropy. Lead in-depth case studies of community-led conservation, with extensive fieldwork in Mexico, including data collection and analysis
-
the U.S., the Global South, and Europe. Furthermore, they will be involved in analyzing, presenting, and publishing data related to the initiative’s ongoing and future projects. The successful candidate
-
big data and AI at its core. A central goal of the project is to build a foundation model of the visual brain—a “digital twin” that captures neural activity and intelligent behavior at unprecedented
-
. Responsibilities: Design and conduct experiments, and generate, analyze and interpret data related to understanding human Treg subtypes in solid tumors, and T cell and Treg bioengineering. Perform in vitro and in
-
University is seeking a postdoctoral scholar to support and lead innovative research at the intersection of rheumatology, pain science, and data science. The successful candidate will work on a portfolio of
-
information of three referees Stanford is an equal opportunity employer and all qualified applicants will receive consideration without regard to race, color, religion, sex, sexual orientation, gender identity
-
, data science, or a related field are encouraged to apply. A candidate who has recently submitted the PhD thesis or is about to submit the thesis is encouraged to apply. A strong computational background
-
. Prevalent TCR clones will undergo reverse engineering to deduce the peptide bound, and this information used to generate MHC tetramers to study the induction of these clones during the anti-tumor response